Download Mobile App

Video Library

Partner Sites

MedImaging

PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack

3D Scanning Approach Enables Ultra-Precise Brain Surgery

X-Ray Breakthrough Captures Three Image-Contrast Types in Single Shot

Novel Imaging Approach to Improve Treatment for Spinal Cord Injuries

Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers

AbbVie Announces Collaboration to Develop Monoclonal Antibody Therapy for COVID-19

By HospiMedica International staff writers
Posted on 09 Jun 2020

A new collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19 will focus on advancing a fully human, neutralizing antibody which targets the conserved domain of the spike protein of SARS-CoV-2.

AbbVie (North Chicago, IL, USA), University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have entered into a collaboration under which AbbVie will support UU, EMC and HBM through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. More...

AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

The fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM targets a conserved region of the virus' spike protein. In cell culture studies the antibody blocked infection by the SARS-CoV-2 and a second coronavirus SARS-CoV. The antibody is fully human, which is designed to facilitate its development and minimize immune-related side effects.

"Treatment and prevention of COVID-19 remains a critical global need. The antibody discovered by UU, EMC and Harbour BioMed is extremely promising based on the mechanism by which it targets the virus and on its developability as a fully human protein," said Tom Hudson, M.D., Senior Vice President, Research and Development and Chief Scientific Officer, AbbVie. "We look forward to working with this outstanding team to advance this antibody towards clinical trials."

"AbbVie is a global leader in developing innovative antiviral therapies," said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. "This collaboration will greatly accelerate our efforts to bring this antibody forward into clinical trials as quickly as possible and contribute a solution to this pandemic."

"The SARS-CoV-2 pandemic has highlighted the importance of understanding coronavirus biology," said Berend-Jan Bosch, PhD, Associate Professor, Research leader at UU. "The collaboration with AbbVie provides an excellent opportunity to translate our research into a clinical candidate with great potential for advancing the fight against this disease."

"The collaboration is an endorsement of our approach to fully human antibody discovery and development. Through this collaboration, we are well positioned to move rapidly towards clinical trials," said Frank Grosveld, PhD, Academy Professor of Cell Biology, EMC, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.

Related Links:
AbbVie
University of Utrecht
Erasmus Medical Centre
Harbor BioMed

Visit expo >

Gold Member

POC Blood Gas Analyzer

Stat Profile Prime Plus

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

New

Syringes

Prefilled Saline Flush Syringes

Pressure Guidewire

SavvyWire

Read the full article by registering today, it's FREE!

Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!